Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details)

v3.3.1.900
Summary of Significant Accounting Policies (Details)
 12 Months Ended
Dec. 31, 2015
USD ($)
Segment
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Summary of Significant Accounting Policies [Line Items]      
Maximum number of days interest bearing instruments with original maturities to consider as cash equivalent 90 days    
Maximum number of days interest bearing instruments with remaining maturities to consider as marketable securities 90 days    
Pre-launch inventory $ 0 $ 0  
Goodwill and intangible assets 2,200,000,000 1,100,000,000  
Amortization of intangible assets 27,977,000 10,919,000 $ 11,133,000
Amortization expense in 2016 51,300,000    
Amortization expense in 2017 50,800,000    
Amortization expense in 2018 47,700,000    
Amortization expense in 2019 44,200,000    
Amortization expense in 2020 42,900,000    
Depreciation 14,200,000 4,000,000 4,100,000
Income tax benefit on release of valuation allowance on deferred tax assets 93,400,000    
Accrual related to uncertain tax positions included in income tax benefit 2,300,000    
Revenue from transfer of intellectual property and other 81,853,000 5,476,000 16,711,000
RXi common stock received 0 0 12,500,000
Total deferred revenue included in accrued expenses and other long-term liabilities 232,900,000 6,700,000  
Accounts receivable 219,043,000 21,875,000  
Allowance for doubtful accounts receivable 25,168,000 1,906,000  
Equity-based compensation expense for continuing operations $ 26,074,000 14,779,000 10,983,000
Number of reportable segments | Segment 2    
Foreign currency transaction gain (loss) $ (2,400,000) (4,800,000) (300,000)
Minimum      
Summary of Significant Accounting Policies [Line Items]      
Intangible assets, estimated useful lives 3 years    
Property, plant and equipment, useful life 5 years    
Estimated tax exposure range $ 0    
Maximum      
Summary of Significant Accounting Policies [Line Items]      
Intangible assets, estimated useful lives 20 years    
Property, plant and equipment, useful life 10 years    
Estimated tax exposure range $ 50,000,000    
Computer Software, Intangible Asset      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 3 years    
Machinery, Medical and Other Equipment | Minimum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 5 years    
Machinery, Medical and Other Equipment | Maximum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 8 years    
Furniture and Fixtures | Minimum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 5 years    
Furniture and Fixtures | Maximum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 10 years    
Land, Buildings and Improvements | Minimum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 10 years    
Land, Buildings and Improvements | Maximum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 40 years    
Automobiles and Aircraft | Minimum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 5 years    
Automobiles and Aircraft | Maximum      
Summary of Significant Accounting Policies [Line Items]      
Property, plant and equipment, useful life 7 years    
RXi Pharmaceuticals Corporation      
Summary of Significant Accounting Policies [Line Items]      
RXi common stock received     12,500,000
Pharmsynthez      
Summary of Significant Accounting Policies [Line Items]      
Sale of rights for certain technologies     $ 3,800,000
Pfizer      
Summary of Significant Accounting Policies [Line Items]      
Revenue from transfer of intellectual property and other $ 65,500,000    
Pfizer | Collaborative Arrangement, Product      
Summary of Significant Accounting Policies [Line Items]      
RXi common stock received 65,500,000    
Total deferred revenue included in accrued expenses and other long-term liabilities 229,500,000    
TESARO | Collaborative Arrangement      
Summary of Significant Accounting Policies [Line Items]      
Milestone payment received 15,000,000    
TESARO | Collaborative Arrangement, Product      
Summary of Significant Accounting Policies [Line Items]      
Milestone revenue recognized 15,000,000 5,000,000  
Government Contracts Concentration Risk      
Summary of Significant Accounting Policies [Line Items]      
Accounts receivable $ 26,100,000 $ 600,000  
Sales Revenue, Net | Government Contracts Concentration Risk      
Summary of Significant Accounting Policies [Line Items]      
Percentage of revenue contributed by customer 9.00% 5.00%  
Self-Pay      
Summary of Significant Accounting Policies [Line Items]      
Percentage of revenue contributed by customer 7.50% 0.50%